2010 Press Releases

Webcast ImageWebcast
MannKind at JMP Securities Life Sciences Conference (Replay)
06/24/15 at 9:30 a.m. ET
Receive E-mail AlertsEmail Alerts
Sign up to receive e-mail alerts whenever MannKind has a news release. Just enter your e-mail address and click submit.
2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
12/28/10MannKind Updates Status of New Drug Application for AFREZZA(R)
VALENCIA, Calif., Dec 28, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that it was informed on December 27, 2010 by the U.S. Food & Drug Administration (FDA) that the agency will not be able to complete the review of the New Drug Application (NDA) for AFREZZA(R) (insulin human [rDNA origin]) Inhalation Powder by the action date of December 29, 2010. The FDA stated that it will require approximately four additional weeks to complete its review of the NDA. About AF... 
Printer Friendly Version
12/07/10Presentation at American Society of Hematology Annual Meeting Confirms Inhibiting Unfolded Protein Response is Promising Treatment for Multiple Myeloma
MannKind Corporation's First-in-Class IRE-1 inhibitor Targets Key Pathway for Restoration of Normal Cell Function ORLANDO, Fla., Dec 07, 2010 (BUSINESS WIRE) -- Researchers at Dana-Farber Cancer Institute in collaboration with MannKind Corporation (Nasdaq:MNKD) generated results confirming that targeting the unfolded protein response (UPR) through the XBP-1 pathway impacts the survival of myeloma cells, suggesting a novel therapeutic strategy in multiple myeloma. The new data generated on a M... 
Printer Friendly Version
12/01/10MannKind to Present at the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference
VALENCIA, Calif., Dec 01, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference on Wednesday, December 8, 2010 at 10:00 AM (PT) at the Nikko Hotel in San Francisco, CA. Interested parties can access a link to the live webcast of the presentation from the News & Media section of th... 
Printer Friendly Version
11/15/10New Findings Show Bioequivalence, Ease-of-Use and Efficiency of MannKind's Drug Delivery Platform
Latest results regarding novel device technology presented at Diabetes Technology Conference VALENCIA, Calif., Nov 15, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD) unveiled new data on its drug delivery, device and particle technologies demonstrating the bioequivalence, ease of use and efficiency of the company's novel platform. The proprietary technology, founded on the company's expertise in inhaled drug development, device engineering and powder formulation performance, was ... 
Printer Friendly Version
11/09/10MannKind to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
VALENCIA, Calif., Nov 09, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Lazard Capital Markets 7th Annual Healthcare Conference on Tuesday, November 16, 2010 at 9:55 AM (EST) at the St. Regis Hotel in New York. Interested parties can access a link to the live webcast of the presentations from the News & Media section of the Company's website at w... 
Printer Friendly Version
11/04/10MannKind Corporation Issues Statement on Lawsuit
VALENCIA, Calif., Nov 04, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD) reported in its recent 10Q filing that a former employee in the regulatory affairs department, Mr. John Arditi, filed a lawsuit for wrongful termination claiming he was retaliated against for raising concerns about the company's clinical trials. The Company today stated that Mr. Arditi's employment was terminated by MannKind's Vice President - Worldwide Regulatory Affairs for legitimate reasons unrelated to his... 
Printer Friendly Version
10/29/10MannKind Corporation Reports 2010 Third Quarter Financial Results
- Conference Call to Begin Today at 9:00 AM EDT - VALENCIA, Calif., Oct 29, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the third quarter ended September 30, 2010. For the third quarter of 2010 total operating expenses were $42.5 million, compared to $42.8 million for the third quarter of 2009, a decrease of $0.3 million. Research and development (R&D) expenses were $31.4 million for the third quarter of 2010 compared to $30.5 million for... 
Printer Friendly Version
10/22/10MannKind Corporation to Hold 2010 Third Quarter Financial Results Conference Call on October 29, 2010
VALENCIA, Calif., Oct 22, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2010 third quarter financial results on Friday, October 29, 2010. Management of the Company will host a conference call to discuss the third quarter financial results and other Company developments at 9:00 AM EDT on October 29, 2010. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice Pr... 
Printer Friendly Version
10/19/10MannKind Announces Initiation of Phase 2 Trial of Cancer Vaccine for Advanced Melanoma
Study to Evaluate the Safety, Tolerability and Clinical Response of MKC1106-MT VALENCIA, Calif., Oct 19, 2010 (BUSINESS WIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced the first patient has been dosed in a phase 2 clinical trial of the novel, investigational cancer vaccine MKC1106-MT. As a part of MannKind's cancer immunotherapy program, this phase 2 study will evaluate the safety, tolerability, immune response and clinical response of MKC1106-MT in patients with advanced melanoma... 
Printer Friendly Version
09/07/10MannKind to Present at Upcoming Conferences
VALENCIA, Calif., Sep 07, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences. Morgan Stanley Global Healthcare Conference on September 13, 2010 at 1:35 PM EDT at the Grand Hyatt in New York, NY Baird Healthcare Conference on September 14, 2010 at 1:45 PM EDT at the St. Regis Hotel in New York, NY Rodman & Renshaw Annual Global... 
Printer Friendly Version
08/23/10MannKind Corporation Providing AFREZZA(R) to Juvenile Diabetes Research Foundation for Artificial Pancreas Project
Investigational, Ultra Rapid Acting Insulin to Be Used in Two-Year Study VALENCIA, Calif., Aug 23, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that the company will supply its novel, ultra rapid acting insulin AFREZZA®   (insulin human [rDNA origin]) for use in a study being conducted by the Juvenile Diabetes Research Foundation (JDRF) as part of its Artificial Pancreas Project. The planned two-year study in patients with type 1 diabetes will leverag... 
Printer Friendly Version
08/19/10MannKind Announces Entry into Stock Lending Agreement
VALENCIA, Calif., Aug 19, 2010 (BUSINESS WIRE) --MannKind Corporation (Nasdaq: MNKD) today announced that it has entered into a previously announced stock lending agreement pursuant to which it will lend 9,000,000 shares of its common stock to Bank of America, N.A. MannKind has also entered into an underwriting agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated ("Merrill Lynch"), an affiliate of Bank of America, pursuant to which Merrill... 
Printer Friendly Version
08/19/10MannKind Announces Pricing of $100 Million Senior Convertible Notes
VALENCIA, Calif., Aug 19, 2010 (BUSINESS WIRE) --MannKind Corporation (Nasdaq: MNKD) today announced the pricing of its previously announced offering of $100 million aggregate principal amount of Senior Convertible Notes due 2015 (the "Notes"). The Notes will be offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), by the financial institutions that are the initial purc... 
Printer Friendly Version
08/16/10MannKind Announces Proposed Offering of Common Stock and Related Share Lending Arrangement
VALENCIA, Calif., Aug 16, 2010 (BUSINESS WIRE) --MannKind Corporation (Nasdaq: MNKD) today announced the commencement of an offering of up to 8,000,000 shares of its common stock. The common stock being offered represent shares of MannKind common stock that MannKind will lend to Bank of America, N.A. Merrill Lynch, Pierce, Fenner & Smith Incorporated ("Merrill Lynch"), an affiliate of Bank of America, is acting as sole book-running manager for ... 
Printer Friendly Version
08/16/10MannKind Announces Proposed Offering of $100 Million Senior Convertible Notes
VALENCIA, Calif., Aug 16, 2010 (BUSINESS WIRE) --MannKind Corporation (Nasdaq:MNKD) today announced that it proposes to offer, subject to market and other conditions, $100 million aggregate principal amount of senior convertible notes due 2015 (the "Notes") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). MannKind also intends to grant to the initial purchasers of the Notes a 13-da... 
Printer Friendly Version
08/11/10MannKind Receives Commitment to Purchase Up to 18,200,000 Shares of Common Stock for Cash
VALENCIA, Calif., Aug 11, 2010 (BUSINESS WIRE) --MannKind Corporation (Nasdaq: MNKD) today announced that it has entered into an agreement with Seaside 88, LP, a private investment limited partnership, for the sale of 700,000 shares of common stock to Seaside 88 every two weeks over the course of a year for a total of up to 18,200,000 shares of MannKind common stock. Each such closing is subject to certain closing conditions. The initial sale of 700,000 ... 
Printer Friendly Version
08/11/10MannKind Receives Commitment from The Mann Group to Reduce Indebtedness in Return for Up to 18,200,000 Shares of Common Stock
VALENCIA, Calif., Aug 11, 2010 (BUSINESS WIRE) --MannKind Corporation (Nasdaq: MNKD) today announced that in addition to the agreement that it has reached with Seaside 88, L.P., which was also announced today in a companion press release, MannKind has entered into an agreement with The Mann Group LLC, an entity controlled by MannKind's chief executive officer and principal stockholder, Alfred Mann, for the parallel sale of shares of common stock to... 
Printer Friendly Version
08/04/10MannKind to Present at the 30th Annual Canaccord Genuity Growth Conference
VALENCIA, Calif., Aug 04, 2010 (BUSINESS WIRE) --MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the 30th Annual Canaccord Genuity Growth Conference on Wednesday, August 11, 2010 at 9 AM (EDT) at the InterContinental Hotel in Boston. Interested parties can access a link to the live webcast of the presentations from the News & Med... 
Printer Friendly Version
08/03/10MannKind's Chairman and CEO Recognized as One of PharmaVOICE's "100 Most Inspiring People in the Life Sciences"
Veteran Entrepreneur is Honored for His Unparalleled Commitment to Medical Research VALENCIA, Calif., Aug 03, 2010 (BUSINESS WIRE) --MannKind Corporation (Nasdaq: MNKD) today announced that the company's chairman and CEO Alfred E. Mann has been named to PharmaVOICE's list of the "100 Most Inspiring People in the Life Sciences." Mr. Mann was recognized for his extraordinary leadership and passion in his lifelong roles as a scientist, inventor, entreprene... 
Printer Friendly Version
08/02/10MannKind Corporation Reports 2010 Second Quarter Financial Results
- Conference Call to Begin Today at 9:00 AM EDT - VALENCIA, Calif., Aug 02, 2010 (BUSINESS WIRE) --MannKind Corporation (Nasdaq:MNKD) today reported financial results for the second quarter ended June 30, 2010. For the second quarter of 2010 total operating expenses were $37.4 million, compared to $53.4 million for the second quarter of 2009, a decrease of $16.0 million. Research and development (R&D) expenses were $26.2 million for the second quarter ... 
Printer Friendly Version
07/26/10MannKind Corporation to Hold 2010 Second Quarter Financial Results Conference Call on August 2, 2010
VALENCIA, Calif., Jul 26, 2010 (BUSINESS WIRE) --MannKind Corporation (Nasdaq:MNKD) will release its 2010 second quarter financial results on Monday, August 2, 2010. Management of the Company will host a conference call to discuss the second quarter financial results and other Company developments at 9:00 AM EDT on August 2, 2010. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating O... 
Printer Friendly Version
07/20/10FDA Accepts AFREZZA Complete Response Resubmission and Sets Target Action Date
VALENCIA, Calif., Jul 20, 2010 (BUSINESS WIRE) --MannKind Corporation (NASDAQ:MNKD) today announced that it has submitted, and the U.S. Food and Drug Administration (FDA) has accepted, MannKind's resubmission of its New Drug Application (NDA) for AFREZZA(TM) (insulin human [rDNA origin]) and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act (PDUFA) action date of December 29, 2... 
Printer Friendly Version
06/28/10AFREZZA(R) Demonstrates Long-Term Efficacy in Controlling Blood Sugar Levels in Patients with Type 2 Diabetes
Two-year findings presented at the American Diabetes Association's 70th Scientific Sessions(R) also show significantly less hypoglycemia than standard of care ORLANDO, Fla., Jun 28, 2010 (BUSINESS WIRE) -- AFREZZA®   (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, investigational ultra rapid acting mealtime insulin, as part of a diabetes treatment regimen, provides long-term glucose control comparable to usual insulin therapy but with a significantly reduced... 
Printer Friendly Version
06/26/10AFREZZA(R) Suppresses Endogenous Glucose Production More Rapidly Than Currently Available Insulin Therapy
Data presented at the American Diabetes Association's 70th Scientific Sessions(R) ORLANDO, Fla., Jun 26, 2010 (BUSINESS WIRE) -- AFREZZA®  (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, investigational ultra rapid acting mealtime insulin, provides more rapid suppression of endogenous glucose production (EGP) after a meal than the subcutaneously-injected insulin lispro in patients with Type 2 diabetes, according to data presented today at the American Diabetes Associa... 
Printer Friendly Version
06/24/10American Diabetes Association/The Lancet Symposium Will Highlight Study Showing AFREZZA(R) Provides Comparable Glycemic Control with Less Weight Gain and Hypoglycemia than Standard of Care
Findings on ultra rapid acting insulin also published in The Lancet ORLANDO, Fla., Jun 24, 2010 (BUSINESS WIRE) --AFREZZA®  (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, investigational ultra rapid acting mealtime insulin, combined with basal insulin is comparable to standard insulin therapy in controlling post-meal blood sugar levels in adult patients with Type 2 diabetes, and offers the added benefits of significantly less weight gain and lower risk of hypoglycemi... 
Printer Friendly Version
06/10/10AFREZZA Demonstrates Non-Inferiority Compared to Standard Therapy in Controlling Blood Sugar Levels in Type 1 Diabetes Patients
Findings Show Reductions in HbA1c Levels, Plus Significantly Lower Rates of Hypoglycemia and Fasting Blood Glucose Levels VALENCIA, Calif., Jun 10, 2010 (BUSINESS WIRE) --MannKind Corporation (NASDAQ: MNKD) today announced that results of a new 16-week trial show that the investigational ultra rapid acting mealtime insulin, AFREZZA(TM) (insulin human [rDNA origin]) Inhalation Powder, combined with basal insulin, is clearly non-inferior to standard thera... 
Printer Friendly Version
06/02/10MannKind to Present at Upcoming Conferences and Annual Stockholders Meeting
VALENCIA, Calif., Jun 02, 2010 (BUSINESS WIRE) --MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences and its annual stockholders meeting. Jefferies 2010 Global Life Sciences Conference on Wednesday, June 9, 2010 at 11:00 AM (EDT) in New York 9th Annual Needham Healthcare Conferenceo... 
Printer Friendly Version
04/30/10MannKind Corporation Reports 2010 First Quarter Financial Results
- Conference Call to Begin Today at 9:00 AM EDT - VALENCIA, Calif., Apr 30, 2010 (BUSINESS WIRE) --MannKind Corporation (Nasdaq:MNKD) today reported financial results for the first quarter ended March 31, 2010. For the first quarter of 2010 total operating expenses were $40.6 million, compared to $57.8 million for the first quarter of 2009. Research and development (R&D) expenses were $30.5 million for the first quarter of 2010 compared to $42.9 million for the same quarter in 2009, a decre... 
Printer Friendly Version
04/27/10MannKind to Present at Upcoming Conferences
VALENCIA, Calif., Apr 27, 2010 (BUSINESS WIRE) --MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences. Deutsche Bank 35th Annual Health Care Conferenceon Tuesday, May 4, 2010 at 4:50 PM (EDT) at the InterContinental in Boston, MA Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 12, 2010 at 3:00 PM (EDT) at the Grand Hyatt in New York... 
Printer Friendly Version
04/23/10MannKind Corporation to Hold 2010 First Quarter Financial Results Conference Call on April 30, 2010
VALENCIA, Calif., Apr 23, 2010 (BUSINESS WIRE) --MannKind Corporation (Nasdaq: MNKD) will release its 2010 first quarter financial results on Friday, April 30, 2010. Management of the Company will host a conference call to discuss the first quarter financial results and other Company developments at 9:00 AM EDT on April 30, 2010. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Offi... 
Printer Friendly Version
04/23/10Follow-up Safety Data Show AFREZZA(R) Comparable to Standard Antidiabetic Therapy in Lung Function Tests
Follow-up Study with Investigational Diabetes Therapy Presented at the American Association of Clinical Endocrinologists 19th Annual Meeting BOSTON, Apr 23, 2010 (BUSINESS WIRE) --Pulmonary function test results (PFTs) in patients treated with AFREZZA®  (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, at follow-up measurements were similar to PFT results observed in patients receiving standard antidiabetic therapy, according to data presented... 
Printer Friendly Version
04/23/10Study Shows AFREZZA(R) Controls Blood Sugar Levels in Type 1 Diabetes, Results in Weight Loss, Less Hypoglycemia Than Usual Care
Two-year data on investigational therapy presented at the American Association of Clinical Endocrinologists 19th Annual Meeting BOSTON, Apr 23, 2010 (BUSINESS WIRE) --Diabetes treatment regimens containing AFREZZA®   (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, provide glucose control similar to standard insulin therapy along with weight loss and reduced incidence of hypoglycemia in patients with Type 1 diabetes and poorly con... 
Printer Friendly Version
03/29/10MannKind Corporation Achieves All Milestones of Research Agreement with Multiple Myeloma Research Foundation to Develop New Therapy
First-in-Class Product Candidate Targets Key Pathway for Restoration of Normal Cell Function NORWALK, Conn. & VALENCIA, Calif., Mar 29, 2010 (BUSINESS WIRE) --The Multiple Myeloma Research Foundation (MMRF) and MannKind Corporation (Nasdaq:MNKD) today announced that MannKind has successfully achieved all milestones of a research agreement with MMRF to develop a novel, first-in-class inhibitor for the treatment of multiple myeloma. The MMRF awarded M... 
Printer Friendly Version
03/24/10MannKind Corporation Wins Prestigious Frost & Sullivan Entrepreneurial Company of the Year Award
Recognition Based on MannKind's Innovative Pipeline of Products and Novel TechnologyVALENCIA, Calif., Mar 24, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that in recognition of the company's accomplishments in the biopharmaceuticals market it has been awarded the prestigious 2010 North America Frost & Sullivan Entrepreneurial Company of the Year Award. Each year, Frost & Sullivan analyzes best practices within the industry ... 
Printer Friendly Version
03/15/10FDA Requests Additional Information Regarding AFREZZA(TM) in Complete Response Letter to MannKind
VALENCIA, Calif., Mar 15, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that it has received a Complete Response letter from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for AFREZZA(TM) (insulin human [rDNA origin]) Inhalation Powder for the treatment of adult patients with type 1 and type 2 diabetes mellitus for the control of hyperglycemia. A Complete Response letter is issued by the... 
Printer Friendly Version
02/24/10MannKind Elects James S. Shannon to its Board of Directors
VALENCIA, Calif., Feb 24, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that James S. Shannon, MD, MRCP (UK) has joined the company's Board of Directors. Dr. Shannon is a recognized pharmaceutical industry leader with more than 20 years of experience in senior leadership positions, including serving as Head of Global Development at Novartis Pharma AG in Basel, Switzerland. The addition of Dr. Shannon brings the total number of... 
Printer Friendly Version
02/02/10MannKind to Present at the 12th Annual BIO CEO & Investor Conference
VALENCIA, Calif., Feb 02, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the 12th Annual BIO CEO & Investor Conferenceon Tuesday, February 9, 2010 at 9 AM (EST) at the Waldorf Astoria Hotel in New York. Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at http://www.ma... 
Printer Friendly Version
02/01/10MannKind Corporation Reports 2009 Fourth Quarter and Full Year Financial Results
- Conference Call to Begin Today at 5:00 PM EST -VALENCIA, Calif., Feb 01, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the fourth quarter and year ended December 31, 2009. For the fourth quarter of 2009, total operating expenses were $55.8 million, compared to $81.8 million for the fourth quarter of 2008. Research and development (R&D) expenses were $43.1 million for the fourth quarter of 2009 compared to $68.8 million for the same quart... 
Printer Friendly Version
01/25/10MannKind Corporation to Hold 2009 Fourth Quarter and Full Year Financial Results Conference Call on February 1, 2010
VALENCIA, Calif., Jan 25, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2009 fourth quarter and full year financial results on Monday, February 1, 2010. Management of the Company will host a conference call to discuss the fourth quarter and full year financial results and other Company developments at 5:00 PM EST on February 1, 2010. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, H... 
Printer Friendly Version
01/11/10MannKind Wins Two Facility of the Year 2010 Category Awards
MannKind's Commercial Manufacturing Facility Earns Accolades for Process Innovation and Equipment Innovation from Worldwide Representatives of the Pharmaceutical and Engineering CommunitiesDANBURY, Conn., Jan 11, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that its commercial manufacturing facility, custom-built for the production of its proprietary insulin therapy, has been awarded two Facility of the Year 2010 category awards for process innovation and equipment... 
Printer Friendly Version
01/08/10MannKind Updates Status of New Drug Application
VALENCIA, Calif., Jan 08, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq:MNKD) announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind's new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010. The FDA explained that it has not yet completed its inspection of the insulin manufacturing facilities of N.V. Organon, a third-party supplier to MannKind. Organon... 
Printer Friendly Version
01/05/10MannKind to Present at the 28th Annual J.P. Morgan Healthcare Conference
VALENCIA, Calif., Jan 05, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the 28th Annual J.P. Morgan Healthcare Conferenceon Tuesday, January 12, 2010 at 1:30 PM (PST) at the Westin St. Francis in San Francisco, California. Interested parties can access a link to the live webcast of the presentations from the News... 
Printer Friendly Version


Print Page Print | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Tear Sheet